Review of Operations Directors’ Report Chairman’s Letter CEO’s Report Financial Report Shareholder Information 3 Annual Report 2026 Dr Leearne Hinch CEO FINANCIAL RESULTS INOVIQ reported a net loss of $7.5 million as it continued to invest in its diagnostic and therapeutic programs, people and quality systems. The Company ended FY26 with $9.4 million in cash. LOOKING AHEAD We believe INOVIQ is entering an exciting growth phase. With a differentiated technology platform, multiple product opportunities, expanding strategic partnerships and a highly experienced team, we are well positioned to create value through innovation, execution and commercialisation. In FY27, our priorities are to: › Complete EXO OC™ development and validation › Progress EXO OC™ toward LDT readiness and US laboratory partnering › Advance CAR exosome therapeutics toward manufacturing readiness and future clinical development › Grow EXO-NET® revenues and expand commercial partnerships › Maintain disciplined capital allocation › Deliver key milestones that support long-term shareholder value We are excited about the opportunities ahead and remain committed to translating scientific innovation into products that can transform patient outcomes while creating meaningful value for our shareholders. Thank you for your continued support and confidence in INOVIQ. We look forward to sharing our progress as we pursue our vision to become a global leader in exosomebased diagnostics and therapeutics.
RkJQdWJsaXNoZXIy MjE2NDg3